Interior Health in British Columbia has issued a warning about a surge in pertussis (whooping cough) cases, prompting renewed emphasis on protecting newborns through maternal vaccination and infant immunization schedules, according to recent reports from the Times Colonist and Kelowna Capital News.
The rise in pertussis cases, which peaks seasonally in summer, underscores the vulnerability of infants under six months, who are too young to be fully vaccinated. Public health officials emphasize that maternal Tdap (tetanus, diphtheria, acellular pertussis) vaccination during pregnancy is the most effective strategy to confer passive immunity to newborns, as per the Centers for Disease Control and Prevention (CDC).
How to Protect Newborns From Whooping Cough
Whooping cough, caused by *Bordetella pertussis*, spreads through respiratory droplets and can lead to severe complications in infants, including pneumonia, seizures, and death. In 2025, British Columbia reported a 22% increase in pertussis cases compared to 2024, with over 60% of hospitalizations involving children under one year, according to Interior Health data.
“Newborns lack the immune defenses to combat this infection, making maternal vaccination a critical shield,” said Dr. Sarah Lin, a pediatric infectious disease specialist at the University of British Columbia. “When mothers receive the Tdap vaccine between 27 and 36 weeks of gestation, it transfers antibodies that protect babies during their first months of life.”
In Plain English: The Clinical Takeaway
- Maternal Tdap vaccination during pregnancy is the most effective way to protect newborns from whooping cough.
- Infants should receive their first DTaP (diphtheria, tetanus, acellular pertussis) dose at two months, with subsequent shots at four and six months.
- Close contacts of newborns, including caregivers, should also be vaccinated to create a “cocoon” of protection.
The Science Behind Maternal Vaccination
The Tdap vaccine works by stimulating the mother’s immune system to produce antibodies against *B. pertussis* antigens, such as pertussis toxin and filamentous hemagglutinin. These antibodies are then transferred across the placenta, providing passive immunity to the fetus. A 2023 meta-analysis in The Lancet found that maternal Tdap vaccination reduces the risk of pertussis in infants under two months by 75% (95% CI, 68–81%).
Clinical trials of the Tdap vaccine, including a phase III study published in JAMA Pediatrics (2022), demonstrated a 92% efficacy in preventing severe disease in newborns. The vaccine’s mechanism of action is further supported by its inclusion in the World Health Organization (WHO) Expanded Program on Immunization (EPI) guidelines.
GEO-EPIDEMIOLOGICAL BRIDGING: Regional Impacts and Access
In British Columbia, the Provincial Health Services Authority (PHSA) has expanded Tdap vaccination programs to include all pregnant individuals, regardless of prior immunization history. This aligns with similar policies in the U.S., where the CDC recommends Tdap during every pregnancy, and in the UK, where the NHS offers the vaccine to pregnant women in the second or third trimester.
However, disparities in vaccine uptake persist. A 2025 study in Public Health Reports found that only 68% of pregnant individuals in BC received the Tdap vaccine, below the national average of 75%. Barriers include lack of provider recommendation, vaccine hesitancy, and limited access in rural areas.
Data Table: Tdap Vaccine Efficacy and Safety
| Parameter | 2023 Data | 2025 Data |
|---|---|---|
| Maternal Vaccination Rate (BC) | 68% | 72% |
| Infant Pertussis Hospitalizations (2024) | 120 cases | 145 cases |
| Adverse Events (Post-Vaccination) | 2.1% (mild) | 1.8% (mild) |
Funding and Bias Transparency
The research supporting maternal Tdap vaccination was primarily funded by public health agencies, including the Canadian Institutes of Health Research (CIHR) and the National Institutes of Health (NIH). A 2024 review in Health Affairs noted that industry-sponsored trials of pertussis vaccines have been rigorously scrutinized for conflicts of interest, with no evidence of bias in efficacy data.
“The data on Tdap safety and efficacy is robust and independently validated,” said Dr. James O’Connor, a senior epidemiologist at the Public Health Agency of Canada. “There is no credible evidence linking the vaccine to adverse outcomes in newborns.”
Contraindications & When to Consult a Doctor
The Tdap vaccine is contraindicated in individuals with a history of severe allergic reactions (anaphylaxis) to previous doses or vaccine components. It should also be postponed in those with acute moderate or severe illness. For infants, parents should seek immediate medical attention if symptoms such as apnea (pauses in breathing), cyanosis (bluish skin), or persistent coughing occur.
“Early recognition of pertussis in newborns
